• A Nature paper proposes a DNA-based non-deterministic universal Turing machine that could achieve exponential speed-ups via massive parallel molecular search, with the authors half-seriously suggesting the multiverse itself might be such a machine.

• The first CRISPR-generated homozygous-knockout human embryos—targeting the fertility “master gene” OCT4—have been reported, reopening debates on germline editing accuracy and ethics.

• Black Hat Europe revealed an exploit that grants arbitrary code execution on Intel Management Engine 11.x even when the host PC is powered off, exposing a new class of below-OS, always-on attack vectors.

• The Global Bio Summit live-stream (YouTube playlist: https://www.youtube.com/watch?v=1V155vBRWEs) showcased DIY bioprinting, cell-free synthetic biology prototyping, and citizen-driven health innovation, with emphasis on biohacking in the global South.

• A programmable dCas9–Dnmt3a–Dnmt3L fusion enables targeted DNA methylation in 4.5-kb windows, producing sharp methylation peaks flanking the PAM site while leaving the binding site itself protected, and has been archived at http://diyhpl.us/diyhpluswiki/gene-editing/.

• Cas9-serine recombinase fusions (RecCas9) extend CRISPR beyond cutting to precise, sequence-specific recombination in mammalian cells, while optogenetic control of dCas9 epigenetic editors allows light-inducible silencing of Ascl1 in neural stem cells.

• Nanopore-based single-molecule DNA sequencing by synthesis uses polymer-tagged nucleotides whose incorporation yields distinct current blockades for real-time base calling, and non-enzymatic chemical labeling of 5-hydroxymethylcytosine now enables direct epigenetic detection in the same platform.

• DNA-origami photolithography masks are under investigation for semiconductor fabrication, with discussion weighing 2-D DNA tiles against protein sheets with engineered holes for practicality.

• IndieBio’s portfolio companies have collectively raised ~$100 M and reached ~$500 M market cap, signaling the maturation of bio-accelerator models, while CAR-T cell therapies are now priced above human kidney transplants, spotlighting genomic-medicine cost challenges.